- Home
- KF vs ELDN Comparison
KF vs ELDN Comparison
Compare KF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- ELDN
- Stock Information
- Founded
- KF 1984
- ELDN 2004
- Country
- KF United States
- ELDN United States
- Employees
- KF N/A
- ELDN N/A
- Industry
- KF Investment Managers
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- ELDN Health Care
- Exchange
- KF Nasdaq
- ELDN Nasdaq
- Market Cap
- KF 128.4M
- ELDN 108.0M
- IPO Year
- KF N/A
- ELDN N/A
- Fundamental
- Price
- KF $33.63
- ELDN $1.67
- Analyst Decision
- KF
- ELDN Strong Buy
- Analyst Count
- KF 0
- ELDN 3
- Target Price
- KF N/A
- ELDN $11.00
- AVG Volume (30 Days)
- KF 18.4K
- ELDN 4.2M
- Earning Date
- KF 01-01-0001
- ELDN 11-14-2025
- Dividend Yield
- KF N/A
- ELDN N/A
- EPS Growth
- KF N/A
- ELDN N/A
- EPS
- KF N/A
- ELDN N/A
- Revenue
- KF N/A
- ELDN N/A
- Revenue This Year
- KF N/A
- ELDN N/A
- Revenue Next Year
- KF N/A
- ELDN N/A
- P/E Ratio
- KF N/A
- ELDN N/A
- Revenue Growth
- KF N/A
- ELDN N/A
- 52 Week Low
- KF $18.30
- ELDN $1.35
- 52 Week High
- KF $25.56
- ELDN $5.08
- Technical
- Relative Strength Index (RSI)
- KF 43.72
- ELDN 33.54
- Support Level
- KF $32.91
- ELDN $1.35
- Resistance Level
- KF $35.06
- ELDN $1.71
- Average True Range (ATR)
- KF 1.01
- ELDN 0.28
- MACD
- KF -0.42
- ELDN -0.11
- Stochastic Oscillator
- KF 32.43
- ELDN 10.86
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.